Back to Search
Start Over
Natural Killer Cells in the Malignant Niche of Multiple Myeloma.
- Source :
-
Frontiers in immunology [Front Immunol] 2022 Jan 11; Vol. 12, pp. 816499. Date of Electronic Publication: 2022 Jan 11 (Print Publication: 2021). - Publication Year :
- 2022
-
Abstract
- Natural killer (NK) cells represent a subset of CD3- CD7+ CD56+/dim lymphocytes with cytotoxic and suppressor activity against virus-infected cells and cancer cells. The overall potential of NK cells has brought them to the spotlight of targeted immunotherapy in solid and hematological malignancies, including multiple myeloma (MM). Nonetheless, NK cells are subjected to a variety of cancer defense mechanisms, leading to impaired maturation, chemotaxis, target recognition, and killing. This review aims to summarize the available and most current knowledge about cancer-related impairment of NK cell function occurring in MM.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Venglar, Bago, Motais, Hajek and Jelinek.)
- Subjects :
- Animals
Biomarkers
Cytotoxicity, Immunologic
Disease Management
Disease Susceptibility
Humans
Immunity
Immunomodulation drug effects
Molecular Targeted Therapy
Multiple Myeloma diagnosis
Multiple Myeloma therapy
Prognosis
Receptors, Natural Killer Cell genetics
Receptors, Natural Killer Cell metabolism
T-Lymphocyte Subsets immunology
T-Lymphocyte Subsets metabolism
Treatment Outcome
Tumor Microenvironment drug effects
Killer Cells, Natural immunology
Killer Cells, Natural metabolism
Multiple Myeloma etiology
Multiple Myeloma metabolism
Tumor Microenvironment immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1664-3224
- Volume :
- 12
- Database :
- MEDLINE
- Journal :
- Frontiers in immunology
- Publication Type :
- Academic Journal
- Accession number :
- 35087536
- Full Text :
- https://doi.org/10.3389/fimmu.2021.816499